{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:20:17Z","timestamp":1791069617889,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejase.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Echocardiography"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.echo.2009.05.002","type":"journal-article","created":{"date-parts":[[2009,6,24]],"date-time":"2009-06-24T10:45:05Z","timestamp":1245840305000},"page":"883-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Role of Serotoninergic Pathways in Drug-Induced Valvular Heart Disease and Diagnostic Features by Echocardiography"],"prefix":"10.1016","volume":"22","author":[{"given":"Sakima A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"de las Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Davila-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.echo.2009.05.002_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors","volume":"79","author":"Modlin","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.echo.2009.05.002_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-8703(54)90152-0","volume":"47","author":"Thorson","year":"1954","journal-title":"Am Heart J"},{"key":"10.1016\/j.echo.2009.05.002_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0002-9343(64)90145-7","article-title":"The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease)","volume":"36","author":"Roberts","year":"1964","journal-title":"Am J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0002-9149(97)00340-8","article-title":"A unique heart disease associated with a unique cancer: carcinoid heart disease","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.echo.2009.05.002_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1541-9215.2005.04044.x","article-title":"Carcinoid heart disease: echocardiographic recognition and differential diagnosis","volume":"3","author":"Pearlman","year":"2005","journal-title":"Am Heart Hosp J"},{"key":"10.1016\/j.echo.2009.05.002_bib7","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","article-title":"Carcinoid heart disease","volume":"116","author":"Bhattacharyya","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ahj.2006.02.019","article-title":"Assessment of patent foramen ovale in carcinoid heart disease","volume":"151","author":"Mansencal","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.echo.2009.05.002_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib11","first-page":"79","article-title":"Cardiac and pulmonary fibrosis during methysergide therapy for headache","volume":"78","author":"Graham","year":"1967","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.echo.2009.05.002_bib12","first-page":"62","article-title":"Mitral regurgitation occurring during methysergide (Sansert) therapy","volume":"101","author":"Munroe","year":"1969","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.echo.2009.05.002_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1540-8175.2003.03027.x","article-title":"Successful repair of aortic and mitral incompetence induced by methylsergide maleate: confirmation by intraoperative transesophageal echocardiography","volume":"3","author":"Joseph","year":"2003","journal-title":"Echocardiography"},{"key":"10.1016\/j.echo.2009.05.002_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1161\/01.CIR.56.5.889","article-title":"Methysergide-Induced heart disease: a case of multivalvular and myocardial fibrosis","volume":"56","author":"Mason","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.2.5915.365","article-title":"Development of heart valve lesions during methysergide therapy","volume":"2","author":"Misch","year":"1974","journal-title":"BMJ"},{"key":"10.1016\/j.echo.2009.05.002_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","article-title":"Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations","volume":"117","author":"Redfield","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.echo.2009.05.002_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00007611-199310000-00024","article-title":"Mitral valve disease associated with long-term ergotamine use","volume":"86","author":"Austin","year":"1993","journal-title":"Southern Med J"},{"key":"10.1016\/j.echo.2009.05.002_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0002-8703(96)90544-X","article-title":"Mitral regurgitation caused by chronic ergotamine use","volume":"131","author":"Flaherty","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.echo.2009.05.002_bib19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/oxfordjournals.eurheartj.a015324","article-title":"Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine","volume":"18","author":"Wilke","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.echo.2009.05.002_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(92)90129-Q","article-title":"Pulmonary hypertension and dexfenfluramine","volume":"339","author":"Atanassoff","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.echo.2009.05.002_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib22","first-page":"1061","article-title":"U.S. Department of Health and Human Services interim public health recommendations, November 1997","volume":"46","year":"1997","journal-title":"Morbid Mortal Wkly Rep"},{"key":"10.1016\/j.echo.2009.05.002_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","article-title":"Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)","volume":"83","author":"Singh","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.echo.2009.05.002_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo","volume":"339","author":"Weissman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199809103391101","article-title":"The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs","volume":"339","author":"Khan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib26","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1161\/01.CIR.100.21.2161","article-title":"Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine","volume":"100","author":"Shively","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0735-1097(99)00321-6","article-title":"Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months","volume":"34","author":"Burger","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.echo.2009.05.002_bib28","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.echo.2009.05.002_bib29","series-title":"FDA analysis of cardiac valvular dysfunction with use of appetite suppressants","year":"1997"},{"key":"10.1016\/j.echo.2009.05.002_bib30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease induced by drugs","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.echo.2009.05.002_bib31","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.echo.2009.05.002_bib32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.echo.2009.05.002_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-Hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kauman","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.echo.2009.05.002_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.echo.2009.05.002_bib37","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","article-title":"Agonism at 5-HT2B receptors is not a class effect of the ergolines","volume":"513","author":"J\u00e4hnichen","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.echo.2009.05.002_bib39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.echo.2009.05.002_bib40","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin-induced up-regulation of transforming growth factor-\u03b21 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.echo.2009.05.002_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib42","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.echo.2009.05.002_bib43","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/eurheartj\/ehm263","article-title":"In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology","volume":"28","author":"Droogmans","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.echo.2009.05.002_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0002-9149(01)01435-7","article-title":"Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation","volume":"87","author":"Mast","year":"2001","journal-title":"Am J Cardiol"}],"container-title":["Journal of the American Society of Echocardiography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0894731709004404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0894731709004404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:44:32Z","timestamp":1760244272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0894731709004404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0894731709004404"],"URL":"https:\/\/doi.org\/10.1016\/j.echo.2009.05.002","relation":{},"ISSN":["0894-7317"],"issn-type":[{"value":"0894-7317","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Serotoninergic Pathways in Drug-Induced Valvular Heart Disease and Diagnostic Features by Echocardiography","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Echocardiography","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.echo.2009.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}